PCRX · XBRL financial data

Viatris financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PCRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	164	181*	167	178	169	187*	169	181	180	197*	177	192
Cost of revenue	40	48*	47	44	39	40*	34	41	34	40*	36	44
Research and development	21	19*	18	20	19	24*	25	28	26	37*	28	30
Selling, general and administrative	68	66*	72	68	74	80*	87	89	92	102*	94	92
Other operating income (expense)	—	—	—	—	—	—	(6)	(1)	—	—	2	(8)
Operating income (loss)	18	33*	13	28	(140)	25*	2	8	6	2*	7	4
Interest income	3	3*	4	5	5	6*	7	5	9	2*	2	2
Interest expense	3	3*	3	4	5	5*	5	5	4	4*	4	4
Other income (expense)	(0)	1*	(0)	(0)	(0)	(0)*	4	(11)	(0)	(0)*	(0)	(0)
Income tax expense (benefit)	6	9*	5	18	5	9*	4	3	4	(1)*	2	(2)
Net income (loss)	11	25*	9	19	(143)	16*	5	(5)	5	2*	3	5
Earnings per share, basic USD per share	0.23	0.54*	0.19	0.41	(3.11)	0.35*	0.10	(0.11)	0.12	0.04*	0.07	0.12
Earnings per share, diluted USD per share	0.23	—	0.19	0.39	(3.11)	—	0.10	(0.11)	0.12	0.04*	0.07	0.12
Weighted average shares, basic millions of shares	46	46*	46	46	46	46*	46	45	44	43*	40	39
Weighted average shares, diluted millions of shares	52	58*	52	51	46	—	47	45	44	44*	41	40

Fiscal quarters (PCRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	99	153	184	247	246	277	284	300	148	159	144	206
Short-term investments	136	125	142	157	208	208	210	145	99	80	58	45
Accounts receivable	97	106	102	105	101	113	105	114	115	124	126	132
Inventory	97	104	97	103	112	125	134	148	158	153	150	135
Prepaid and other current assets	19	22	19	20	24	22	28	37	43	33	37	30
Total current assets	447	510	543	632	690	745	760	746	563	548	515	615
Property and equipment, net	176	174	172	169	167	167	164	155	147	141	136	130
Right-of-use asset	63	61	59	56	54	49	49	47	44	42	39	45
Goodwill	163	163	163	163	0	0	22	20	20	20	20	20
Total assets	1,534	1,574	1,583	1,647	1,522	1,554	1,587	1,537	1,298	1,265	1,209	1,244
Accounts payable	17	16	9	19	19	19	23	30	18	15	14	18
Accrued liabilities	60	64	67	65	76	80	80	71	80	96	85	93
Current portion of long-term debt	—	—	—	—	—	202	—	—	—	0	—	—
Total current liabilities	94	97	93	93	306	310	315	313	107	121	109	122
Long-term debt	—	—	—	—	—	384	—	—	377	372	368	363
Lease liability, non-current	57	55	52	50	48	45	44	41	39	36	34	39
Total liabilities	703	704	691	768	772	775	788	779	570	572	555	572
Accumulated deficit	(132)	(107)	(98)	(79)	(222)	(206)	(202)	(206)	(201)	(199)	(196)	(192)
Total stockholders' equity	832	870	892	879	750	778	799	758	727	693	654	672
Total liabilities and equity	1,534	1,574	1,583	1,647	1,522	1,554	1,587	1,537	1,298	1,265	1,209	1,244
Common shares outstanding (cover page) millions of shares	46	47	47	46	46	46	46	45	43	40	39	40

Fiscal quarters (PCRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	11	25*	9	19	(143)	16*	5	(5)	5	2*	3	5
Stock-based compensation	13	12*	13	13*	13*	12*	15	15*	14*	13*	14	15*
Depreciation and amortization	18*	18*	18	19*	20*	21*	21	27*	21*	21*	21	21*
Net cash from operating activities	44*	48*	49	53*	54*	33*	35	12*	61*	44*	26	57*
Purchases of property and equipment	3*	2*	3	2*	4*	2*	9	3*	4*	0*	3	1*
Net cash from investing activities	(4)*	8*	(16)	(15)*	(52)*	(0)*	(26)	62*	44*	19*	19	12*
Share repurchases	0*	0*	—	—	0*	0*	0	50*	50*	48*	50	0*
Net cash from financing activities	(28)*	(2)*	(3)	25*	(3)*	(2)*	(3)	(58)*	(257)*	(52)*	(59)	(8)*
Net change in cash	12*	54*	31	63*	(1)*	31*	7	17*	(153)*	11*	(14)	62*

No SIC code on file for this company, so there is no peer list.

No peers in the same industry and size range yet.

Not investment advice. Not affiliated with the U.S. SEC.